References
- McLean IW. The biology of haematogenous metastasis in human uveal malignant melanoma. Virchows Arch A 1993; 422: 433–7
- Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003; 44: 4651–9
- Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metastases from ocular melanoma: Imaging study in 110 patients. Am J Roentgenol 1991; 157: 1279–81
- Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S, Kivelä T. A prognostic model and staging for metastatic uveal melanoma. Cancer 2003; 97: 465–75
- Eskelin S, Pyrhönen S, Summanen P, Hahka-Kemppinen M, Kivelä T. Tumor doubling times in metastatic malignant melanoma of the uvea: Tumor progression before and after treatment. Ophthalmology 2000; 107: 1443–9
- Kivelä T, Eskelin S, Kujala E. Metastatic uveal melanoma. Int Ophthalmol Clin 2006; 46: 133–49
- Kodjikian L, Grange JD, Baldo S, Baillif S, Garweg JG, Rivoire M. Prognostic factors of liver metastases from uveal melanoma. Graefes Arch Clin Exp Ophthalmol 2005; 243: 985–93
- Peters S, Voelter V, Pampallona S, Popescu R, Gillet M, Bosshard W. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: Experience in 101 patients. Ann Oncol 2006; 17: 578–83
- Aoyama T, Mastrangelo MJ, Berd D, Nathan FE, Shields CL, Shields JA, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer 2000; 89: 1561–8
- Egerer G, Lehnert T, Max R, Naeher H, Keilholz U, Ho AD. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: A single-center experience with seven patients. Int J Clin Oncol 2001; 6: 25–8
- Schmittel A, Schmidt-Hieber M, Martus P, Bechrakis NE, Schuster R, Siehl JM, et al. A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 2006; 17: 1826–9
- Schmittel A, Schuster R, Bechrakis NE, Siehl JM, Foerster MH, Thiel E, et al. A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma. Melanoma Res 2005; 15: 447–51
- Pföhler C, Cree IA, Ugurel S, Kuwert C, Haass N, Neuber K, et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: Results of a multicenter feasibility study. Anticancer Drugs 2003; 14: 337–40
- Eskelin S, Summanen P, Pyrhönen S, Tarkkanen A, Kivelä T. Screening for metastatic uveal melanoma revisited. Cancer 1999; 85: 1151–9
- Kivelä T, Suciu S, Hansson J, Kruit WH, Vuoristo MS, Kloke O, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003; 39: 1115–20
- Nathan FE, Berd D, Sato T, Shield JA, Shields CL, De PP, et al. BOLD+interferon in the treatment of metastatic uveal melanoma: First report of active systemic therapy. J Exp Clin Cancer Res 1997; 16: 201–8
- Pyrhönen S, Hahka-Kemppinen M, Muhonen T, Nikkanen V, Eskelin S, Summanen P, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer 2002; 95: 2366–72